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Cha, Bong-Soo, Theodore P. Ciaraldi, Kyong-Soo Park, Leslie
Carter, Sunder R. Mudaliar, and Robert R. Henry. Impaired
fatty acid metabolism in type 2 diabetic skeletal muscle cells is
reversed by PPAR agonists. Am J Physiol Endocrinol Metab
289: E151–E159, 2005. First published February 22, 2005;
doi:10.1152/ajpendo.00141.2004.—The impact of type 2 diabetes on
the ability of muscle to accumulate and dispose of fatty acids and
triglycerides was evaluated in cultured muscle cells from nondiabetic
(ND) and type 2 diabetic (T2D) subjects. In the presence of 5 M
palmitate, T2D muscle cells accumulated less lipid than ND cells
(11.5  1.2 vs. 15.1  1.4 nmol/mg protein, P  0.05). Chronic
treatment (4 days) with the peroxisome proliferator-activated recep-
tor- (PPAR) agonist troglitazone increased palmitate accumulation,
normalizing uptake in T2D cells. There were no significant differ-
ences between groups with regard to the relative incorporation of
palmitate into neutral lipid species. This distribution was also unaf-
fected by troglitazone treatment. -Oxidation of both long-chain
(palmitate) and medium-chain (octanoate) fatty acids in T2D muscle
cells was reduced by 40% compared with ND cells. Palmitate
oxidation occurred primarily in mitochondrial (40–50% of total)
and peroxisomal (20–30%) compartments. The diabetes-related de-
fect in palmitate oxidation was localized to the mitochondrial com-
ponent. Both palmitate and octanoate oxidation were stimulated by a
series of thiazolidinediones. Oxidation in T2D muscle cells was
normalized after treatment. Troglitazone increased the mitochondrial
component of palmitate oxidation. Skeletal muscle cells from T2D
subjects express defects in free fatty acid metabolism that are retained
in vitro, most importantly defects in -oxidation. These defects can be
corrected by treatment with PPAR agonists. Augmentation of fatty
acid disposal in skeletal muscle, potentially reducing intramyocellular
triglyceride content, may represent one mechanism for the lipid-
lowering and insulin-sensitizing effects of thiazolidinediones.
type 2 diabetes mellitus; fatty acid oxidation; thiazolidinediones;
mitochondria
THE METABOLIC PROFILE OF TYPE 2 DIABETES includes impaired
glucose metabolism and insulin resistance; these are frequently
combined with dyslipidemia as well as insulin resistance for
control of free fatty acid (FFA) and triglyceride (TG) metab-
olism. Members of the thiazolidinedione class of antidiabetic
drugs have been shown to ameliorate aspects of this dyslipi-
demia, as well as improve glucose metabolism (27). Because
FFAs are the major fuel source for skeletal muscle in the
fasting and exercising states, impairments in FFA metabolism
in skeletal muscle would be expected to have a major impact
on energy homeostasis. Indeed, the literature contains reports
that both obese and type 2 diabetic individuals oxidize lower
than normal amounts of fatty acids in muscle in the fasting
state (5, 33, 37, 38, 40, 59).
If not oxidized, FFA can accumulate as TG in skeletal
muscle, potentially impacting insulin action. A strong inverse
correlation between intramyocellular TG (IMTG) content and
insulin action has been established across a wide weight range
of nondiabetic and type 2 diabetic subjects (reviewed in Refs.
26, 35). It has been postulated that it is the accumulation of
intermediates of fatty acid metabolism, and not just IMTG
itself, that contributes to the development of insulin resistance
(22, 67). The processes involved in this TG accumulation in
muscle are numerous, including the mass action effect of
elevated circulating FFA levels due to augmented adipose
tissue lipolysis in obese and diabetic individuals (16). Also
contributing to this accumulation is the fact that obese indi-
viduals favor fatty acid esterification and storage over oxida-
tion in skeletal muscle (59).
Lipid metabolism is a highly complex and tightly regulated
process. FFAs are provided in the circulation by both release
from lipoproteins, by the action of lipoprotein lipase, and
lipolysis in adipose tissue. A key regulated process after that is
FFA entry into cells. FFAs have been shown to diffuse pas-
sively across the cell membrane (reviewed in Ref. 25). In
addition, it has been proposed that a portion of FFA uptake is
protein mediated (reviewed in Ref. 8). Once inside the muscle
cell, FFAs are either incorporated into lipids by esterification
for storage and structural purposes or oxidized in mitochondria
and peroxisomes. After production of fatty acid CoA deriva-
tives by acetyl-CoA synthase, entry of long-chain fatty acid
CoA into mitochondria is mediated by carnitine palmitoyl-
transferase I (CPT I), a crucial regulatory point in lipid and
glucose metabolism (47), whereas medium-chain fatty acids
enter the mitochondria independently of CPT I (47).
To investigate the nature of lipid metabolism in skeletal
muscle of type 2 diabetic patients, independent of the hyper-
glycemia, hyperinsulinemia, and hyperlipidemia present in
vivo, we utilized human skeletal muscle cells in culture. When
differentiated, cultured human skeletal muscle cells display
many of the morphological, biochemical, and metabolic char-
acteristics of mature skeletal muscle (28). Most importantly,
cells from diabetic subjects display defects in glucose and fatty
acid metabolism that are reflective of the subject’s in vivo
metabolic status (19, 20, 28, 29). Muscle cells from diabetic
subjects also display insulin resistance for the control of
glucose metabolism (15, 19). In this study, multiple steps in
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FFA metabolism were compared between nondiabetic and type
2 diabetic muscle cells before and after treatment with agonists
for the peroxisome proliferator-activated receptor- (PPAR).
These include de novo synthesis, incorporation into lipids, and
-oxidation to evaluate potential mechanisms that could con-
tribute to increased levels of fatty acids and/or intermediates in
insulin-resistant muscle.
MATERIALS AND METHODS
Subjects. Thirty patients with type 2 diabetes and 39 nondiabetic
subjects provided muscle tissue for the studies. Of the type 2 diabetic
patients, 22 were treated with oral antidiabetic agents (glipizide and
metformin), 3 with insulin in combination with an oral agent, and 5
with diet alone. Diabetic patients had their medication withheld on the
morning of biopsy. Nondiabetic subjects were not taking any medi-
cations known to influence glucose and lipid metabolism. Glucose
tolerance was determined in all subjects after a 75-g oral glucose
tolerance test. In vivo insulin action was determined by a 3-h eugly-
cemic (5.0–5.5 mM) hyperinsulinemic (1,800 pmol m2 min1)
clamp; the glucose disposal rate was determined during the last 30
min of the clamp (62). Subjects did not exercise for at least 24 h
before the procedure. Clinical characteristics of the subjects are
summarized in Table 1. On average, the diabetic subjects were older
and more obese than the nondiabetic subjects. However, there were no
associations between either age or body-mass index and in vitro
measures of FFA oxidation (not shown). In addition, matching sub-
jects within the groups for age and obesity did not alter the in vitro
results and conclusions; therefore, the entire nondiabetic population
was included. The experimental protocol was approved by the Com-
mittee on Human Investigation of the University of California, San
Diego. Informed, written consent was obtained from all subjects after
explanation of the protocols.
Materials. Cell culture materials were purchased from Irvine Sci-
entific (Irvine, CA) except for skeletal muscle basal medium, which
was obtained from Clonetics (San Diego, CA). [9,10-3H]palmitate,
D-[U-14C]glucose, and [14C]acetate were obtained from NEN Life
Science Products (Boston, MA). [8-3H]octanoate was supplied by
American Radiolabeled Chemicals (St. Louis, MO). Unlabeled palmi-
tate octanoate and FFA-free BSA were purchased from Sigma (St.
Louis, MO). Reagents for electrophoresis, as well as the AG-1X8
resin, were obtained from Bio-Rad (Richmond, CA). A polyclonal
antibody against human muscle-specific CPT I (mCPT I) was pur-
chased from Alpha Diagnostics (San Antonio, TX); phosphoserine
(S79)-specific antibody against acetyl-CoA carboxylase (ACC) was
purchased from Upstate (Lake Placid, NY). Anti-rabbit IgG com-
plexed to horseradish peroxidase and Hyperfilm were from Amersham
(Arlington Heights, IL). SuperBlock and SuperSignal chemilumines-
cent substrate kits were obtained from Pierce (Rockford, IL). Trogli-
tazone was a kind gift from Dr. Alan Saltiel (formally of Pfizer
Parke-Davis Pharmaceuticals, Ann Arbor, MI), rosiglitazone was a
gift from Dr. Steven Smith (GlaxoSmithKline), and pioglitazone was
supplied by Dr. A. Kozai (Takeda Pharmaceuticals America, Lincoln-
shire, IL).
Muscle biopsy and cell culture. Needle biopsies of the vastus
lateralis muscle were completed before insulin infusion. The methods
for muscle cell isolation and growth have been described in detail
previously (28). At 80–90% confluence, cells were fused for 4 days in
-MEM containing 2% FBS, 1% fungibact, 100 U/ml penicillin, and
100 g/ml streptomycin. Fusion medium was changed every other
day. Approximately 90% of the cells take on the multinucleated
morphology characteristic of mature, differentiated myotubes (28);
fibroblasts were not detected in the cultures. When indicated, 11.5 M
troglitazone, 10 M rosiglitazone, or 10 M pioglitazone was added
for 4 days at the initiation of fusion and differentiation. The doses of
agents were determined in preliminary studies such that maximal
stimulation of palmitate oxidation was provided. Agents were dis-
solved in DMSO (final concentration of 0.05%). This treatment
protocol does not alter the extent of differentiation of myocytes into
mature myotubes (data not shown).
Measurement of FFA oxidation. The procedure for assaying palmi-
tate and octanoate oxidation is a modification of a method established
for adherent cells (56). Cells were incubated in serum-free media
containing substrate ([9,10-3H]palmitic acid or [8-3H]octanoic acid,
0.2 Ci, final concentration of 5 M) in a 95% O2-5% CO2 incubator
at 37°C for 3 h. After incubation, a 100-l aliquot of the culture
medium was placed over an ion-exchange resin, and the column was
washed twice with 0.75 ml of water. Intact FFA (charged state) was
retained by the resin, whereas 3H released during oxidation was
incorporated into water, which passes freely through the resin column.
To learn more about the sites of palmitate oxidation in diabetic
muscle, we exploited the differential sensitivity of long-chain fatty
acid CoA uptake across the organelle membrane for inhibition by
etomoxir (3), using this property to discriminate between the mito-
chondrial and peroxisomal pathways of FFA -oxidation. The oxida-
tion of [3H]palmitate measured in untreated cells would be total
oxidation. The portion of palmitate oxidation occurring in the mito-
chondria is irreversibly inhibited by a low concentration of etomoxir
(1 M). The peroxisomal component of palmitate oxidation is revers-
ibly inhibited by a high dose (50 M) of etomoxir. Residual palmitate
oxidation is considered to occur by other, undefined processes.
Extraction and analysis of cellular lipids. Myotubes were incu-
bated with [3H]palmitate (as described for the FFA oxidation assay),
[14C]glucose (as described for measurement of glucose incorporation
into glycogen; see below), or [14C]acetate and washed, and then lipids
were extracted with CHCl3-MeOH (2:1). Parallel wells of cells were
solubilized with 0.1 N NaOH to determine total cell-associated radio-
activity. The extracted lipids were sampled for determination of
radioactivity or separated by TLC in heptane-isopropyl ether-acetic
acid (60:40:3). Spots were visualized with rhodamine solution under
UV light and excised, and radioactivity was determined. Lipid species
were identified by comigration with commercially available standards.
Glycogen synthesis. Glucose incorporation into muscle glycogen
was determined as previously described (29) from the incorporation of
D-[U-14C]glucose (0.5 Ci, final glucose concentration of 5 mM) in
the absence or presence of maximal (33 nM) insulin concentrations
for 2 h. Results are expressed as nanomoles of glucose converted to
glycogen per milligram of protein per hour. Total cellular protein was
determined by the Bradford method (10).
Cell protein extraction. Extraction buffer (20 mM Tris HCl, 145
mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton X-100, 0.5%
Nonidet P-40, 200 M sodium vanadate, 200 M PMSF, 1 M
leupeptin, 1 M pepstatin, 10 g/ml aprotinin, 100 mM NaF, and 40
mM sodium pyrophosphate, pH 7.4) was added to confluent mono-
layers of fused myotubes, which had been treated for 4 days. Cells
were scraped into tubes and solubilized by incubating for 30 min on
Table 1. Subject characteristics
Nondiabetic type 2 Diabetic
No. of subjects (women/men) 39 (16/23) 30 (4/26)
Age, yr 442 532*
BMI, kg/m2 29.01.1 34.71.5*
Fasting glucose, mM 5.10.1 9.60.6*
Fasting insulin, pM 686 20833*
Hb A1c, % 5.50.1 8.70.4*
GDR, mgkg1min1 10.060.47 5.690.34*
TG, mg/dl 11110 18820*
FFA, mM 0.3910.026 0.4870.039*
Values are means  SE. BMI, body mass index; FFA, free fatty acids; GDR,
glucose disposal rate determined from hyperinsulinemic (300 mUm2min1),
euglycemic (5.0–5.5 mM) clamp procedure; Hb A1c, hemoglobin A1 glycosylate;
TG, triglyceride. *P  0.025 vs. nondiabetic.
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ice with frequent mixing; this was followed by centrifugation at
14,000 g for 10 min at 4°C. We analyzed the supernatant fluid (total
cell lysate) for protein content using the Bradford method (10).
Western blotting. The method for Western blot analysis was de-
scribed previously (28). Equal amounts of total extracted cell proteins
were loaded and separated on 10% SDS-PAGE gels and then trans-
ferred to a nitrocellulose membrane (63). All samples from the same
individual set of cells were analyzed on the same gel. The secondary
antibody for mCPT I and ACC serine phosphorylation was anti-rabbit
IgG conjugated with horseradish peroxidase. We detected immuno-
complexes using an enhanced chemiluminescence kit according to the
manufacture’s instructions, followed by autoradiography. Quantifica-
tion was performed with a scanning laser densitometer (Scan Analy-
sis; Biosoft, Cambridge, UK). A sample of human skeletal muscle
protein was included on each gel to serve as a control for intergel
variability.
Statistical analyses. Statistical significance was evaluated using
Student’s t-test, and two-tailed P values were calculated. Paired
analysis was performed for comparisons of chronic effects of each
agonist. Significance was accepted at the P  0.05 level. Because of
the limited number of cells available, we did not conduct every study
in each subject. Clinical characteristics of the subsets of subjects
studied in the different experiments did not differ from the average of
the total group; this held true for both nondiabetic and diabetic
subjects.
RESULTS
Lipid synthesis. De novo synthesis was the first aspect of
lipid metabolism evaluated in cultured muscle cells. Glucose
incorporation into total lipid (lipogenesis), defined as incorpo-
ration into organic extractable material, was modest, represent-
ing only 1% of the amount of glucose incorporated into
glycogen over the same period (Table 2). Lipogenesis from
glucose was not acutely stimulated by insulin and was similar
in nondiabetic and type 2 diabetic muscle cells. This behavior
differs from that of glycogenesis, which was reduced in dia-
betic muscle and is acutely insulin responsive (Table 2).
Lipogenesis from acetate was considerably greater than from
glucose (Table 2) and was also not insulin responsive. There
was a tendency for lipogenesis from acetate to be elevated in
diabetic muscle cells (P  0.1).
Fatty acid accumulation and esterification. After incubation
of muscle cells with 5 M palmitate for 3 h, palmitate accu-
mulation by muscle cells from diabetic subjects was reduced to
70% of the value in nondiabetic cells (Fig. 1). This result is
consistent with our recent finding that carrier-mediated palmi-
tate uptake is impaired in diabetic muscle cells (66). Treatment
with the PPAR agonist troglitazone increased palmitate ac-
cumulation in cells from both groups, but the difference was
statistically significant only in the type 2 diabetic cells. After
treatment, the significant difference between groups was lost;
impaired palmitate accumulation in diabetic muscle was re-
stored to the level seen in untreated nondiabetic cells. After
incubation with [3H]palmitate, essentially all (98–99%) of the
cell-associated radioactivity was present in the lipid extract.
One half (50%) of the lipid-associated radioactivity migrated in
the chromatographic solvent used, which was selected to sep-
arate neutral lipid species; the balance remained at the origin.
Of the radioactivity that migrated, 65–75% was present in a
peak identified as TG, with the remainder in diacylglycerol,
monoacylglycerol, cholesterol esters, and other, unidentified
forms (Fig. 2). The relative distribution of [3H]palmitate be-
tween these lipid species did not differ significantly between
nondiabetic and diabetic muscle, although there was a ten-
dency toward greater incorporation into diacylglycerol in type
2 diabetic cells. Troglitazone treatment did not significantly
alter the relative pattern of palmitate incorporation into lipid
species (data not shown).
Fatty acid oxidation. The major fate of fatty acids in the
muscle cell is oxidation. The oxidation of palmitate in type 2
diabetic muscle cells was impaired, compared with nondiabetic
muscle (Fig. 3A). In a subset of subjects, oxidation of the
medium-chain fatty acid octanoate was measured in parallel
with that of palmitate. Even when substrate concentrations
were matched (5 M), muscle cells oxidized less octanoate
(Fig. 4A): 41  5% and 47  5% of the amount of palmitate
oxidized in nondiabetic and type 2 diabetic cells, respectively.
Both palmitate and octanoate oxidation were reduced in type 2
diabetic muscle cells (Fig. 4A) and to a similar extent, 40%
lower than nondiabetic samples.
As reported previously by our laboratory (13), 50% of
palmitate oxidation in nondiabetic muscle occurs in mitochon-
dria (Fig. 3B). The difference in palmitate oxidation between
the diabetic and nondiabetic groups is seen in the mitochon-
drial component (Fig. 3B). Peroxisomal oxidation of palmitate
Table 2. Glycogen and lipid synthesis in human skeletal
muscle cells
Substrate
and
Treatment
Nondiabetic type 2 Diabetic
Glycogen Lipid Glycogen Lipid
Glucose
Basal 4.420.65 0.0390.008 2.700.33* 0.0340.008
	Insulin 7.781.48† 0.0350.007 5.101.21† 0.0350.007
Acetate
Basal 0.140.04 0.260.08
	Insulin 0.0980.01 0.260.08
Values are averages  SE; n 
 8 nondiabetic subjects and 6 diabetic
subjects. Results are presented as nmol of substrate incorporated into glycogen
or lipid after 2-h exposure to glucose (5 mM) or acetate (1 mM) 	 glucose,
normalized to protein content (1 mg). Insulin (33 nM) was present, when
indicated, during the 2-h period. *P  0.05 vs. nondiabetic. †P  0.05 vs.
basal.
Fig. 1. Palmitate accumulation by human skeletal muscle cells. Myotubes
were incubated with [3H]palmitate (5 M final concentration) for 3 h at 37°C
and washed, and cell-associated radioactivity was determined. Cells were
treated with troglitazone (Tgz, 11 M) for 4 days. Results are averages 	 SE;
n 
 4 for nondiabetic (ND) and 3–7 for type 2 diabetic (T2D). *P  0.05
vs. ND.
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is similar in normal and diabetic muscle. Although total palmi-
tate oxidation was lower in the subsets of subjects studied for
this analysis compared with the values for each entire group,
the differences between nondiabetic and type 2 diabetic cells
were still present for both mitochondrial and total palmitate
oxidation (Fig. 3B).
Chronic treatment (4 days) of muscle cells with several
different thiazolidinediones resulted in stimulation of both
palmitate (Fig. 5A) and octanoate (Fig. 4B) oxidation. Because
the responses of palmitate oxidation to troglitazone rosiglita-
zone and pioglitazone were similar, indicating that this is a
class effect, the results for the different thiazolidinediones were
combined for each subject group. Octanoate oxidation was
measured only in pioglitazone-treated cells. With treatment,
palmitate oxidation in diabetic cells did not differ from the
activity in control nondiabetic cells; thiazolidinedione treat-
ment normalized long-chain fatty acid oxidation in diabetic
muscle. The same was true for octanoate oxidation. The in-
crease in palmitate oxidation in response to treatment was due
entirely to a change in the mitochondrial component (Fig. 5B)
in both nondiabetic and diabetic muscle cells.
Regulation of protein expression and phosphorylation. Be-
cause the rate-controlling step for mitochondrial -oxidation of
long-chain fatty acids in mitochondria is transit across the outer
mitochondrial membrane (47), mediated by CPT I, regulation
of the expression of mCPT I was evaluated. mCPT I protein
was readily detectable in cultured muscle cells (Fig. 6A). The
extent of protein expression was similar in nondiabetic and
diabetic muscle cells (Fig. 6B). Because the responses of
mCPT I protein to both troglitazone (11 M) and pioglitazone
(10 M) were comparable (not shown), the results for the two
agents were combined. Thiazolidinedione treatment resulted in
a modest decrease in mCPT I protein expression: 88  9% of
control in nondiabetic (P 
 not significant) and 73  9% in
type 2 diabetic (P  0.05) cells.
mCPT I is also under allosteric control by malonyl-CoA, the
product of a reaction catalyzed by ACC (57). Because ACC is
deactivated by serine phosphorylation, this property was eval-
uated under the same conditions as mCPT I expression. In the
control state, there was no difference in ACC phosphorylation
between nondiabetic and type 2 diabetic cells (Fig. 7). Piogli-
tazone treatment resulted in an increase in ACC phosphoryla-
tion; this difference did not attain statistical significance in
either individual group (P 
 0.058–0.060) but was highly
significant when the groups were pooled (P  0.025).
DISCUSSION
type 2 diabetes is recognized as a disease of disorders of
both glucose and lipid metabolism. Circulating FFA levels are
elevated in diabetic individuals, due in large part to elevated
basal lipolysis from adipose tissue depots, together with a
reduced ability of insulin to suppress stimulated lipolysis
(reviewed in Ref. 43). The critical importance of elevated
circulating FFA levels in diabetic and obese individuals was
demonstrated in both rodents and humans, where FFA infusion
was shown to generate whole body insulin resistance (6, 7, 18,
23). Although the impact of circulating FFA is major, recent
attention has focused on the influence of fat accumulated
within muscle, termed intramyocellular lipid or IMTG, on
Fig. 3. Palmitate oxidation in human muscle cells. Myotubes were incubated
with [3H]palmitate (5 M final concentration) for 3 h at 37°C. Products of
oxidation were monitored as 3H2O released to the media. A: absolute rates of
total palmitate oxidation in untreated cells. Results are average 	 SE; n 
 39
for ND and n 
 30 for T2D. B: components of palmitate oxidation, as defined
in the text. Results are averages; n 
 5 for ND and 9 for T2D. *P  0.05 vs.
ND.
Fig. 2. Palmitate incorporation into lipid in human muscle cells. Myotubes
were incubated with [3H]palmitate as described in Fig. 1, and lipids were
extracted and analyzed as described in MATERIALS AND METHODS. Lipid species
were identified by comigration with commercial standards: CE, cholesterol
esters; TG, triglycerides; DG, diglycerides; MG, monoglycerides. Results are
presented as % of total counts that migrated from the origin in that spot,
determined for each individual set of cells. Results are averages 	 SE; n 
 3
for ND and 4 for T2D.
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insulin action and glucose metabolism. Multiple investigators
have reported strong associations between IMTG and the
presence of insulin resistance in diabetic and nondiabetic
individuals (5, 6, 34, 65). However, this relationship is not
absolute; there is a paradox for endurance-trained athletes, who
are highly insulin sensitive, because they also display high
IMTG (21). Thus factors other than the total amount of IMTG,
such as the accumulation of fatty acid intermediates (1, 26, 67),
may contribute to insulin resistance.
There could be several reasons for excess IMTG and fatty
acid intermediates in diabetic and obese individuals. One
would be the mass action effect of increased substrate delivery
to muscle, from the elevated circulating FFA levels. There
could also be a change in the ultimate fate of FFA, with greater
esterification and storage and less disposal through oxidation.
Both behaviors have been observed in diabetic (4, 9, 37) and
obese (31) individuals. What is uncertain is how much of this
behavior of diabetic muscle is acquired from the hyperlipid-
emic and dysmetabolic environment present in vivo, whether
this is perhaps potentially reversible, and whether this is
perhaps an intrinsic property of diabetic muscle. It is these
questions that we addressed in human skeletal muscle cells
maintained in culture under defined conditions. Our group (28,
49) and others (19, 42) have reported that muscle cells from
type 2 diabetic subjects maintain, at least in part, defects in
glucose uptake, glycogen synthesis, and insulin signaling that
are reflective of the behaviors observed in vivo. Less is known
about lipid metabolism under these circumstances, although it
has recently been reported that cultured skeletal muscle cells
from type 2 diabetic subjects do display impaired palmitate
oxidation (20), in agreement with the present results.
De novo lipid synthesis in cultured skeletal muscle was
found to be modest, and not insulin responsive, whether as
acetate incorporation into FFA or glucose formation of the
glycerol backbone of TGs (Table 2). The latter is not surpris-
ing, as muscle, unlike adipose tissue under most conditions,
contains glycerol kinase (24) and can reuse glycerol released
by lipolysis. When extracellular FFA levels are matched be-
tween nondiabetic and diabetic muscle, as is possible in the
cultured cell system, diabetic muscle cells accumulate less
palmitate, at least at low substrate levels. This finding is in
agreement with our laboratory’s recent report (66), where we
found the protein-mediated component of FFA uptake to be
reduced in diabetic muscle cells, and with in vivo results from
limb balance and flux studies that demonstrated defects in FFA
uptake in diabetic muscle (5) when differences in substrate
levels were controlled for. The incorporation of palmitate into
neutral lipid species in diabetic muscle cells is reduced to the
same extent as total accumulation, suggesting that esterifica-
tion may be intact. It is interesting to note that there is a
tendency for there to be relatively more diacyglycerol present
in diabetic muscle (Fig. 2), although this difference did not
attain statistical significance. This may be of importance be-
cause it has been suggested that, more so than total IMTG, it
may be the presence of specific lipid metabolites, such as
ceramide or diacyglycerol, that modulate insulin action (1, 22,
26, 67).
The major observation of our present work is that the
oxidation of both palmitate and octanoate is significantly im-
paired in diabetic muscle cells. Although the diabetic subjects
studied were, on average, older and more obese than the
nondiabetic subjects, there were no significant associations
between these two parameters and rates of fatty acid oxidation
in muscle cells. These results in cultured myotubes are in
agreement with in vivo data (45, 37); by matching FFA levels,
both acutely and chronically, between the nondiabetic and
diabetic groups, we show that defects in FFA oxidation are
likely an intrinsic property of diabetic muscle, although addi-
tional impairments may be acquired from the hyperglycemic,
hyperinsulinemic, and hyperlipidemic environment present in
vivo. A similar in vitro finding for palmitate oxidation has
recently been reported (20). The magnitude of the reduction in
palmitate oxidation (40%) is greater than that seen for total
uptake. The net result of such a difference would suggest that,
in diabetic muscle, a greater proportion of FFA entering the
cell would be stored, leading to increased IMTG and interme-
diates, which would be consistent with observations made in
both in vivo (1, 55), at least in obesity, and in vitro (20)
systems. It must be noted that the present observations were
made when FFA levels in the media were the same for
nondiabetic and diabetic muscle cells. The contribution of the
diabetes-related defect in FFA oxidation to increased IMTG
Fig. 4. Octanoate oxidation in human muscle cells. Myotubes were incubated
with [3H]octanoate (5 M final concentration) or palmitate for 3 h at 37°C. A:
absolute rates of palmitate and octanoate oxidation measured in the same
subjects’ cells. Results are averages 	 SE; n 
 6 for ND and n 
 9 for T2D.
FFA, free fatty acid. B: regulation of octanoate oxidation. Cells were treated
for 4 days in the absence (control) or presence of pioglitazone (	Pio, 10 M)
before assay. Results are averages 	 SE; n 
 6 for ND and 9 for T2D. *P 
0.05 vs. ND. †P  0.05 vs. control for same individual.
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would be accentuated by the elevated substrate supply avail-
able to diabetic muscle in vivo (Table 1). We have previously
shown (13) that a major portion (50%) of the -oxidation of
palmitate occurs in the mitochondria. The impairment in FFA
oxidation in diabetic muscle cells appears to be localized to the
mitochondrial component. The finding that defects exist for
both palmitate and octanoate oxidation indicates that there are
perturbations in common aspects of FFA metabolism. This
behavior would be consistent with other observations, such as
the finding that the activities of enzymes involved in mitochon-
drial oxidation of fatty acids are reduced in muscle biopsies
from diabetic subjects (11, 36, 58), as are the expression of
many mitochondrial genes of oxidative metabolism (53).
The fate of exogenous FFA between -oxidation and incor-
poration into storage forms such as mono-, di-, and triacylglyc-
erol is subject to multiple levels of control. The key control
point for mitochondrial -oxidation of long-chain fatty acids is
passage of long-chain fatty acyl-CoA esters across the outer
mitochondrial membrane, mediated in skeletal muscle by
mCPT I, whereas medium-chain fatty acids like octanoate do
not require CPT I to enter the mitochondria (47). Conversely,
the committed rate-limiting step for glycerolipid synthesis is
performed by glycerol 3-phosphate acyltransferase (61). Im-
paired palmitate oxidation in diabetic muscle cells could be the
result of defects in the expression and/or function of mCPT I,
a reciprocal increase in glycerol-3-phosphate acyltransferase
activity, or a decreased oxidative capacity of the mitochondria;
Fig. 5. Regulation of palmitate oxidation in skeletal muscle
cells. Cells were treated for 4 days, during fusion/differen-
tiation with Tzd (10–11 M) before assay of palmitate
oxidation. A: total oxidation. Results are averages 	 SE;
n 
 25–37 for ND and 23–30 for T2D. B: components of
oxidation. Results are averages; n 
 5 for ND and 9 for
T2D. *P  0.05 vs. ND. †P  0.05 vs. control for same
individual.
Fig. 6. Regulation of muscle-specific carnitine palmitoyltransferase (mCPT I)
protein expression in muscle cells. A: representative Western blot. B: quanti-
tation of expression. Results from Tgz and Pio treatments were combined for
each group. Results are averages 	 SE; n 
 9 for ND and 8 for T2D. AU,
arbitrary units. *P  0.05 vs. control.
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there is in vivo evidence for this latter possibility (36, 54, 58),
which would be consistent with the shared impairments in
long- and medium-chain FFA oxidation reported here. CPT I
activity has been found to be reduced in muscle of insulin-
resistant obese individuals (33); however, the impact of type 2
diabetes on CPT I activity in muscle is unknown, although it
was recently reported that the mRNA expression of CPT I is
normal in diabetic muscle (17). This last observation would
suggest that any reduction in CPT I activity may be acquired in
nature, due primarily to allosteric factors, as is also indicated
by the fact that physiological hyperglycemia with hyperinsu-
linemia is able to decrease long-chain fatty acid oxidation even
in healthy subjects (55). Reduced FFA oxidation is accompa-
nied by lower functional CPT I activity and elevations in the
muscle content of malonyl-CoA (55). This observation is
crucial because CPT I activity is under well-defined allosteric
control, where the lipogenic precursor malonyl-CoA inhibits
CPT I activity and subsequent FFA oxidation (55, 57). Because
malonyl-CoA is synthesized by ACC, inactivating phosphory-
lation of ACC would reduce malonyl-CoA levels, ameliorating
the inhibition of CPT I and permitting increased FFA oxidation
(57). The importance of allosteric regulation would also be
consistent with the present results in cultured muscle cells,
where there were no differences between nondiabetic and type
2 diabetic muscle cells with regard to mCPT I protein expres-
sion (Fig. 6), similar to the behavior in muscle tissue (17);
rather, control may lay at the level of CPT I activity and
malonyl-CoA concentrations in the vicinity of the mitochon-
dria. Although malonyl-CoA levels were not measured directly
in our study, the tendency for increased phosphorylation of
ACC in muscle cells after thiazolidinedione treatment (Fig. 7)
would be expected to lower malonyl-CoA levels. In addition,
the presence of reductions in medium-chain fatty acid oxida-
tion indicates that diabetes-related defects in FFA oxidation
occur distal to the action of CPT I as well. The ability of
thiazolidinedione treatment to improve long-chain fatty acid
oxidation could involve effects at any or all of these steps.
Consequences of a diabetes-related impairment in FFA ox-
idation in skeletal muscle could include increased lipid storage
in muscle, elevated IMTG and fatty acid metabolism interme-
diates, and diversion of excess FFA to other tissues (4).
Elevated intracellular lipid contents of muscle and liver have
been strongly associated with insulin resistance (34, 65), al-
though lipid accumulation in the pancreas has been shown to
lead to -cell toxicity (41). Thiazolidinedione treatment of
diabetic individuals has been shown to reduce both circulating
FFA levels (46, 48) and IMTG (46) and improve insulin
sensitivity, even while increasing subcutaneous adipose tissue
mass (39, 46). Many of these effects have been attributed to an
increase in adipose tissue differentiation and diversion of lipid
stores from other tissues (liver, muscle, and -cell) to this
expanding adipose tissue mass, termed the lipid steal hypoth-
esis (45, 64). These responses would also be consistent with a
more active role in skeletal muscle to reduce IMTG by increas-
ing fatty acid oxidation, thereby disposing of a portion of the
stored lipid and intermediates, as suggested by the present
results. It is most likely that both mechanisms, the lipid steal
and increased disposal in muscle, are contributing to the
thiazolidinedione-induced changes in circulating and tissue
FFA content and the resulting improvement in insulin action.
Similar to the situation in vivo, thiazolidinedione treatment of
human skeletal muscle cells has been shown to improve both
insulin signaling (32) and insulin responsiveness (51). The fact
that thiazolidinedione treatment ameliorates both defective
FFA oxidation and insulin resistance, in vivo and in vitro,
indicates a close relationship, possibly causal, between these
two aspects of the metabolic phenotype of diabetic muscle.
Thiazolidinediones are known to be selective agonists for
the nuclear receptor PPAR (60). PPAR protein is present in
skeletal muscle (44) and muscle cells (1, 53), although not to
the same level as in adipose tissue (44). Evidence in cultured
muscle cells (2, 51, 66), transgenic animals depleted of adipose
tissue (12, 14), and muscle-specific knockouts of PPAR (30,
50) supports a role for direct effects of PPAR in muscle on
control of metabolism. Although troglitazone, rosiglitazone,
and pioglitazone display differing affinities for PPAR (60),
the fact that maximally effective doses of the three compounds
have similar effects on palmitate oxidation suggests that this
response is a family effect, most likely mediated through
PPAR.
In summary, skeletal muscle cells from type 2 diabetic
subjects express intrinsic defects in FFA metabolism that are
retained in vitro, including impaired accumulation and defects
in -oxidation. These defects can be corrected by treatment
with PPAR agonists. The abilities of PPAR-activating
agents to improve glucose tolerance and insulin action may
involve effects on both glucose and lipid metabolism in skel-
etal muscle in addition to the well-characterized actions in
adipose tissue.
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